215 Efficacy of sarilumab in combination with csDMARDs in patients with rheumatoid arthritisand inadequate response to TNF inhibitors by baseline levels of diseaseactivity

Abstract

Background: Sarilumab is a human mAb blocking the IL‐6Ra. In the Phase III TARGET study (NCT01709578), sarilumab (150 or 200mg subcutaneously every 2 weeks [q2w]) plus conventional synthetic (cs) DMARDs demonstrated efficacy in adults with active, moderate‐tosevere RA and intolerance of or inadequate response to TNF inhibitors. Most common treatment‐emergent adverse events were infections, neutropenia, injection site reactions, increased lipids, and increased transaminases. It has been postulated that, in clinical trials, patients with higher baseline disease activity are more likely to show response than those with lower baseline disease activity. The objective of this post hoc analysis was to examine the efficacy of sarilumab in patient subgroups based on median baseline disease activity levels. Methods: All patients in TARGET randomised to placebo (n=181), sarilumab 150mg q2w (n=181), and sarilumab 200mg q2w (n=184) were included. Disease activity at baseline was defined according to